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Background: Caesarean section is a commonly performed operation worldwide. It has been found to increase
rates of maternal infectious morbidities more than five times when compared to vaginal delivery. Provision of
intravenous prophylactic antibiotics 30 to 60 minutes prior to caesarean section has been found to reduce
post-caesarean infection tremendously. Many centers recommend provision of a single dose of antibiotics, as
repeated doses offer no benefit over a single dose.
At Bugando Medical Centre post caesarean infection is among the top five causes of admission at the post-natal
ward. Unfortunately, there is no consistent protocol for the administration of antibiotic prophylaxis to patients who
are designated for caesarean section. Common practice and generally the clinician’s preference are to provide
repeated dosages of antibiotic prophylaxis after caesarean section to most of the patients. This study aims to
determine the comparative efficacy of a single dose of gentamicin in combination with metronidazole versus
multiple doses for prevention of post caesarean infection.
Methods/Design: The study is an interventional, open-label, two-armed, randomized, single-center study
conducted at Bugando Medical Centre Mwanza, Tanzania. It is an ongoing trial for the period of seven months; 490
eligible candidates will be enrolled in the study. Study subjects will be randomly allocated into two study arms; “A”
and “B”. Candidates in “A” will receive a single dose of gentamicin in combination with metronidazole 30 to 60
minutes prior to the operation and candidates in “B” will receive the same drugs prior to the operation and
continue with gentamicin and metronidazole for 24 hours. The two groups will be followed up for a period of one
month and assessed for signs and symptoms of surgical site infection.
Data will be extracted from a case record form and entered into Epi data3.1 software before being transferred to
SPSS version 17.0 for analysis. The absolute difference in proportion of women who develop surgical site infection
in the two study arms will be the effectiveness of one regime over the other.
Trial registration: Current Controlled TrialsISRCTN44462542.
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Postpartum infection remains among the top five causes
of pregnancy-related maternal mortality and morbidity
worldwide [1-3]. Women who undergo caesarean section
have a 5- to 20-fold greater risk of postpartum infection
than women having a vaginal delivery [4-7]. The incidence
of post-cesarean infection varies widely worldwide from
2.5% to 20.5% [8-12].
Post-caesarean infections are polymicrobial, involving
aerobes, anaerobes and ureaplasma. The main source of
postpartum infection after caesarean section is the lower
genital tract, particularly if the membranes are ruptured,
but this still occurs with intact membranes following pre-
term birth. The most common isolated pathogens are anae-
robes and gram-negative aerobes. Gram-negative aerobes
include Escherichia coli, Klebsiella spp, Enterobacter spp.
and Proteus spp. The anaerobes include Bacteroides spp.,
Clostridium spp., and Fusobacterium spp. [8-10]. However,
exogenous bacterial contamination by skin flora (such as
Staphylococcus aureus) as a result of a break in sterile
technique, may occur, especially following a difficult or
complicated surgery [11]. Mawalla et al., in a prospective
cross-sectional study, reported that most common isolates
in surgical site infection at Bugando Medical Centre are
gram-negative bacteria. Staphylococcus aureus was found
in only 28.6% of study patients; and 18.8% were MRSA
(Methicillin resistant Staphylococcus aureus) [12].
Selection of antibiotics for prophylaxis follows the
principle that the selected antibiotic regimen should
have activity against the microbial agent commonly
involved in surgical site contamination and actual infec-
tion. A combination of clindamycin and aminoglycosides
has been recommended as the treatment of choice in
post-caesarean infection, since it covers most of the
pathogenic bacteria commonly involved. Alternatively, a
combination of metronidazole with aminoglycosides has
been found to be effective in some studies [8,10,13,14].
Apart from being a drug of choice in treating gram-
negative bacteria, methicillin sensitive Staphylococcus
aureus responds to gentamicin [14-16].
A number of well-designed studies have documented
the efficacy of prophylactic antibiotics in reducing the
rates of post-partum infection among patients who have
undergone caesarian section [17-21]. Administration of
antibiotic prophylaxis within an hour prior to skin inci-
sion is more effective in reducing post-caesarean infec-
tious morbidity when compared to administration of the
same drugs after cord clamping, and has no effect on
neonatal infection [22-26]. Owens et al., in a systematic
review, reported that provision of antibiotic prophylaxis
for caesarean section before skin incision compared with
after umbilical cord clamping is associated with a 40%
decrease in postpartum endometritis and a 30% decrease
in wound infection [27].Provision of a single dose of antibiotics preoperatively
has been found to be as effective as multiple doses, in
prevention of postpartum infection [28,29].
At Bugando Medical Centre (BMC), the rate of caesar-
ian is estimated to be 20% [30]. All patients who deliver
by caesarian section receive antibiotic prophylaxis. There
is no consistent protocol for administration of antibiotic
prophylaxis for patients designated for caesarean section
The common practice is to provide repeated doses of
prophylactic antibiotics for at least 24 hours after caesar-
ian section and often on individual clinicians’ practice
and preference. Gentamicin and metronidazole are
among the antibiotics which are used as prophylaxis for
infection during caesarean delivery.
This study aims to compare the efficacy of an intra-
venous single dose of gentamicin (3 mg/Kg) plus metro-
nidazole 500 mg given 30 to 60 minutes before incision
and multiple doses of gentamicin (3 mg/Kg) plus metro-
nidazole (500 mg) 30 to 60 minutes before incision and
every 8 hours for 24 hours postoperatively.
Justification for this study
Caesarean section remains an important risk factor for
post-partum infection in many health facilities. Surgical
site infection post-caesarean section is among the top
five causes of admission in the postnatal ward at
Bugando Medical Centre. There is no consistent proto-
col for provision of prophylactic antibiotics at our ob-
stetric unit. Therefore, the findings from this study will
help to improve the quality of care by using standard
protocol for antibiotic prophylaxis among patients
undergoing caesarean section.
Study hypothesis
In this study, the hypothesis is: “there is no clinically sig-
nificant difference between a single dose of gentamicin in
combination with metronidazole and multiple doses over
24 hours for prevention of post caesarean infection".
Methods/Design
Study design and site
This is an interventional, open label, two-armed, rando-
mized, single center study to be conducted at BMC, a
zonal consultant and teaching hospital situated in
Mwanza City, Tanzania. In this hospital, 7,149 pregnant
women are admitted yearly. There are 6,868 deliveries
per annum, 1,398 (20.3%) pregnant women deliver by
caesarean section [30].
Targeted population
The targeted study population is all pregnant women
who are admitted at the BMC labor ward and planned
for emergency caesarean section.
Lyimo et al. Trials 2012, 13:89 Page 3 of 5
http://www.trialsjournal.com/content/13/1/89Sample size estimation
The incidence of surgical site infection ranges between
2.5% and 20%. Zelenitsky et al., in his prospective rando-
mized study, found that deep surgical site infection rates
were 8.1% and 6.9% in the single high dose and multiple
standard dose groups, respectively [31].
For the purpose of this study, which involves candi-
dates who undergo emergency or non-elective caesarean
section, we use Ps = 8.1%, which is the proportion of par-
ticipants in the single dose antibiotic prophylaxis group
expected to develop surgical site infection post caesarian
section, and Pn = 6.9%, which is proportion of partici-
pants in the multiple dose antibiotic prophylaxis
expected to develop surgical site infection. If we assume
the hypothesized difference, D to be 5%, the sample size
needed to reject this hypothesis at alpha = 0.05 and
beta = 0.20 is [32]:
Z0:95 þ Z0:80ð Þ2 Ps 1 Psð ÞPn þ 1 Pnð Þ½ 
= Ps Pn Dð Þ2
Substituting to the formula, the total required sample
size: 444 (that is, the required sample size in each group
will be 222).
When considering 10% of participants drop out or are
lost to follow-up, the required sample size will be 490;
that is, each group will contain 245 participants.
Eligibility/Enrollment
After the decision for caesarean section is made, the
pregnant woman will be assessed to see if she is eligible
for this study. The assessment for eligibility will be based
on inclusion and exclusion criteria given below.
Inclusion criteria
All pregnant women who planned for caesarean section
and have consented for the study are eligible for inclu-
sion in the study.
Exclusion criteria
All pregnant women with fever (temperature of 38°C
and above), prolonged obstructed labor and premature
rupture of membranes (rupture of membrane more than
12 hours will be excluded. Pregnant women presenting
with features of chorioamnionitis (that is, foul smelling
lochia, uterine tenderness associated with fever), allergic
to the antibiotics used in the study or those who have
used antibiotics in the 24 hours preceding the operation
will also be excluded.
Randomization
Intervention will start after allocating eligible candidates
into two study arms: A and B.Study arm A will be those who will receive a single
intravenous single dose of gentamicin (3 mg/Kg) plus
metronidazole 500 mg 30 to 60 minutes before oper-
ation. Study arm B will be those who will receive mul-
tiple doses of gentamicin (3 mg/Kg) plus metronidazole
(500 mg) 30 to 60 minutes before operation and metro-
nidazole 500 mg every 8 hours for 24 hours.
Simple randomization will be used to allocate study
participants. About 490 opaque envelopes of the same
size and color will be prepared for this study. A total of
245 envelopes will contain papers marked “study arm A”
and the remaining envelopes will contain papers marked
“study arm B”. Then all envelopes will be mixed thor-
oughly in a box before selection of an envelope is done.
Each study participant will select one sealed envelope
and give it to the research assistant to open. Then, she
will be administered antibiotic prophylaxis according to
the study allocation group.
Primary outcome measures
Surgical site infection will be our primary outcome - the
assessment for any evidence of surgical site infection will
be done 72 hours after caesarian section, as well as on
follow-up days (Day 7 and Day 30 post-caesarean sec-
tion). Two clinicians in the ward who are not aware of
the study group allocation will perform diagnosis of sur-
gical site infection. The presence of fever (febrile mor-
bidity), signs and symptoms of abdominal wound
infection or endometritis will indicate surgical site infec-
tion. Febrile morbidity will be defined by temperature
above 38°C at least 4 hours apart on two or more occa-
sions, excluding the first 24 hours after delivery [33].
Abdominal wound infection will be defined by partial or
total dehiscence or presence of purulent or serous dis-
charge from the wound with indurations, warmth and
tenderness.
Endometritis will be defined by the presence of fever
(38°C or above) in association with one or more of the
following: uterine tenderness or foul smelling lochia
[33]. In both groups, the bladder catheter will be
removed after 24 hours. Wound care will follow the
standard scheme in both groups, the occlusive dressing
applied in the theatre and removed after 48 hours. The
patient will be discharged on Day 3 if there is no sign of
infection or complication and asked to return on Day 7
in order to have her stitches removed. Then, the patient
will return on Day 30 post-caesarean section for re-
assessment. On Day 7 and Day 30, axillary temperature
will be measured, and the abdomen and wound will be
examined for signs of infection and sutures will be
removed on the first follow-up visit.
Secondary outcome measure
There are no secondary outcome measures.
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All data will be extracted from patients’ files and filled in
a case record form designed for this study. Data to be
collected will include the woman’s socio-demographic
characteristics, obstetric history (past and present), and
labor history if any (stage of labor, state of amniotic
membrane-whether intact or ruptured) and others. In-
formation on the HIV status of all women will also be
collected. Patients’ information will be added during fol-
low up.
Data management
Data will be entered in Epi data 3.1 software (Epidata
Association, Odense, Denmark) and later transferred
into SPSS version 17.0 (University of Chicago, Chicago,
USA) for analysis. Cleaning will be done using the same
package.
Data analysis
Analysis will involve baseline and hypothesis testing.
Baseline analysis will involve comparing of the baseline
characteristics between the two study arms. Hypothesis
testing will be done to determine if there is a significant
difference in cumulative incidence of post-caesarian in-
fection between women under single dose antibiotic
regimen and those under the multiple-doses antibiotic
regimen. The analysis will be done as per protocol. The
absolute difference in the proportion of women who will
develop surgical site infection in the two study arms will
be the effectiveness of one regimen over the other.
Results will be presented in cumulative incidence and as
a relative ratio together with 95% confidence intervals
and P-value. Sub-group analysis will be performed by lo-
gistic regression to determine the association between
surgical site infection and other covariates, such as HIV
status, duration of operation, stage of labor and so on.
Covariates with P-value less than 0.05 will be considered
significant. Efforts will be made to trace by calling those
who will be lost to follow so as to determine their well-
being, this information will be incorporated into the data
collection form (Additional file 1).
Quality control
The principal investigator will review data daily from
case record forms (CRF) for completeness and consist-
ence of the responses.
Two data clerks, ensuring that entered data quality
will not rely on a single person, will conduct data entry.
Where discrepancies are found, the two data entry clerks
will be called together with the CRF to rectify the
difference.
Participation refusal or the decline from study of a sig-
nificant number of eligible women (more than 30%) may
create uncertainty in the internal validity of the study.Efforts will be made to explain to all eligible women
the nature of the study and its importance for improving
the care of women delivering by caesarean section at
Bugando. We anticipate an attrition rate of 10% or less.
Study participants will be reminded to attend their
follow-up days through contact phone numbers pro-
vided by them.
Data dissemination and utilization
Apart from being part of a dissertation proposal for FL,
effort will be made to publish the final results. Import-
antly, the findings will be used to create a protocol for
use of antibiotics as operative prophylaxis.
Ethical approval
This trial does not involve new drugs, only timing of ad-
ministration of drugs is being tested; however, Good
Clinical Practice (GCP) and the Declaration of Helsinki
are observed. Clearance was sought from the Bugando
Research Ethics Committee on 22 August 2011, ref:
BREC/001/39/2011.
An informed consent will be requested from partici-
pants after explaining the study aims. For literate women,
the consent information will be provided followed by pro-
viding a copy of the consent form that each participant
will be required to sign to signify her consent.
For non-literate women, the consent information sheet
will be read in full and participants required to place a
thumb print on the consent form to signify their accept-
ance to participate in the study. A nurse or doctor who
is not part of the study will be around to witness and
verifiy the counseling process for illiterate women.
Participation is voluntary and those declining to par-
ticipate will still be entitled to the standard care pro-
vided to all women in the labor ward.
Regarding testing for HIV, the current policy is that every
woman admitted at Bugando Medical Centre is requested
to be tested for HIV. A trained counselor is available in the
labor room to counsel all women coming for delivery. Test-
ing is done according to the Tanzania Ministry of Health
recommendation. The filled data collection form will be
destroyed after data entry and cleaning.
Trial status
The recruitment of patients started 1 October 2011, and
it is expected that by 15 May 2012 the required sample
size will be reached.
Additional file
Additional file 1: Algorithm for Randomization.
Abbreviations
BMC: Bugando medical centre; CRF: Case record forms; GCP: Good clinical
practice; MRSA: Methicillin resistant Staphylococcus aureus.
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